Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Microbiome Diagnostics Partners (MDP)

Enterome SA, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in multiple diseases areas, including inflammatory bowel diseases (IBD) and liver diseases. MDP will be a 50/50 joint venture between Enterome and Nestlé Health Science. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of diagnostics in all therapeutic areas except immuno-oncology. Prometheus Laboratories (a Nestlé Health Science Company) will contribute its diagnostics development and commercialization expertise. Nestlé Health Science will invest €20 million in return for its 50% stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities. MDP will be governed by a Board, with Pierre Belichard, CEO of Enterome becoming Chairman. Warren Cresswell, General Manager and Head of Prometheus Diagnostics, will become a Board member of MDP and assume the role of MDP CEO. Initially, MDP will focus on developing diagnostics for the assessment and management of IBD based on Enterome’s IBD110 microbiome-derived mucosal healing biomarker and on the development of diagnostic products for progressive liver diseases [non-alcoholic fatty liver disease, (NAFLD), including non-alcoholic steatohepatitis (NASH)] based on Enterome’s MET210 biomarker. Prometheus will provide its serum-based biomarkers to both development programs. *

 

Period Start 2017-07-11 established jv 50/50
  Group Nestlé (Group)
Products Industry diagnostics (medical/biological)
  Industry 2 microbiomics
Persons Person Cresswell, Warren (Nestlé 201707 General Manager + Head of Prometheus Diagnostics + CEO of MDP)
  Person 2 Belichard, Pierre (Enterome 201203 CEO)
     
  City n. a. 
    Address record changed: 2017-07-19
     
Basic data Employees n. a.
     
    * Document for »About Section«: Enterome S.A.. (7/11/17). "Press Release: Enterome and Nestlé Health Sciences Launch New Diagnostics Company". Paris.
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Nestlé (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px




» top